Prevention you can rely on

Nearly no emesis in both the acute
and delayed phases1

Complete response (no emesis and no use of rescue medication)1

Multiple Cycle Efficacy
*Secondary endpoint.
  • Nearly 100% of patients receiving cisplatin experienced complete response during the acute phase with AKYNZEO1
Primary endpoint: complete response in overall phase (0-120 hours)2
  • Complete response = no emesis and no use of rescue medications. This means that no rescue antiemetic agent was administered through 5 days2
Primary endpoint results: 90% of patients experienced a complete response in the overall phase with AKYNZEO vs 77% with oral palonosetron (p=0.003)1
Study design in patients receiving high-dose cisplatin1
Multicenter, randomized, double-blind, double-dummy, parallel-group study evaluating AKYNZEO (300 mg netupitant/0.5 mg palonosetron) (n=135) vs oral palonosetron (n=136)
  • Day 1: AKYNZEO + dexamethasone 12 mg vs palonosetron 0.5 mg + dexamethasone 20 mg
  • Days 2-4: Dexamethasone 8 mg once a day vs dexamethasone 8 mg twice a day
Patients received cisplatin (≥50 mg/m2 either alone or in combination with other chemotherapy agents)2
  • Patients received a high dose of cisplatin; without prophylaxis, this gives them more than a 90% risk of developing CINV3
  • 86% of AKYNZEO patients received concomitant chemotherapy along with cisplatin, potentially further increasing their risk of emetic events2,3
  • Median cisplatin dose: 75 mg/m2 for each group2
Patients treated with AKYNZEO primarily had a diagnosis of lung/respiratory cancer (25.9%), head and neck cancer (24.4%), or ovarian cancer (17.8%)2

A lasting response through 6 cycles1,4†

Acute and Delayed Efficacy
Secondary endpoint.
95% confidence interval.
  • Complete response in the delayed phase was higher with AKYNZEO among patients receiving chemotherapy with AC during all cycles (Cycles 2-6)1
Primary endpoint results: 77% of patients experienced a complete response in the delayed phase with AKYNZEO vs 70% with oral palonosetron (p=0.001)1
Study design in patients receiving AC1
Phase III, multinational, multicenter, randomized, double-blind, double-dummy, parallel-group study evaluating AKYNZEO (300 mg netupitant/0.5 mg palonosetron) (n=724) vs oral palonosetron (n=725)1,5
  • Day 1: AKYNZEO + dexamethasone 12 mg vs palonosetron 0.5 mg + dexamethasone 20 mg1
  • Days 2-3: No antiemetic treatment1
After completion of Cycle 1, patients had the option to participate in a multiple-cycle extension, receiving the same treatment as assigned in Cycle 11
  • 88.4% of patients continued treatment in the multiple-cycle extension1
  • 62.3% of patients completed the multiple-cycle extension up to a maximum of 8 treatment cycles1

Complete response in the delayed phase was higher with AKYNZEO during all cycles (Cycles 2-6)1

CINV=chemotherapy-induced nausea and vomiting.
AC=anthracycline-cyclophosphamide.